4,540 Shares in Gilead Sciences, Inc. $GILD Bought by TRB Wealth Management LLC

TRB Wealth Management LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 4,540 shares of the biopharmaceutical company’s stock, valued at approximately $574,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences during the 4th quarter worth about $25,000. Persistent Asset Partners Ltd bought a new position in shares of Gilead Sciences in the 2nd quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC grew its holdings in shares of Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 85 shares in the last quarter. Quattro Advisors LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $26,000. Finally, Wealth Preservation Advisors LLC increased its position in shares of Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 81 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently commented on GILD shares. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 5th. Daiwa Securities Group dropped their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 19th. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Weiss Ratings cut shares of Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. Finally, Needham & Company LLC restated a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a report on Wednesday, August 5th. Twenty-four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $158.04.

Gilead Sciences Trading Up 1.9%

Gilead Sciences stock opened at $146.12 on Friday. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The stock has a market capitalization of $181.18 billion, a P/E ratio of -54.73 and a beta of 0.32. The stock has a 50-day simple moving average of $131.97 and a 200 day simple moving average of $136.59.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.01 earnings per share. Analysts expect that Gilead Sciences, Inc. will post -0.51 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences’s payout ratio is presently -122.85%.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the transaction, the chief executive officer directly owned 592,133 shares of the company’s stock, valued at $77,160,851.23. The trade was a 2.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $138.36, for a total transaction of $415,080.00. Following the completion of the transaction, the chief financial officer owned 165,646 shares in the company, valued at approximately $22,918,780.56. This represents a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 87,000 shares of company stock valued at $11,562,960 over the last 90 days. 0.30% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.